Psyrin - Serious mental illness
Psyrin detects serious mental illnesses through AI-powered voice technology. SMIs affect over 145 million people worldwide, reducing expected life expectancy by 15-20 years.
Headquarters
London, UK
Founded
2022
Stage
Early
Clinical Stage
Feasibility
Challenge
Serious Mental Illnesses (SMIs) are a pressing concern in the UK, impacting millions and reducing life expectancy by 15-20 years. Conventional diagnostic and treatment methods are insufficient and often invasive. Psyrin aimed to revolutionize this area by utilizing their AI-powered voice technology to detect SMIs effectively.
Results
Through the Neuroute platform, Psyrin was able to identify three optimal sites within the UK for their groundbreaking clinical trials. These sites were not only technologically advanced but also had staff who could be quickly trained on the Neuroute platform, and most importantly, catered to a high volume of potential SMI patients. This meticulous planning and execution, facilitated by Neuroute, also garnered significant investor attention.
Patient cohorts analyzed
Studies analyzed
Process
SMI Feasibility: The first step involved conducting an indication analysis specifically tailored to serious mental illnesses like Schizophrenia, Bipolar Disorder, Major Depressive Disorder, and Obsessive-Compulsive Disorder. Psyrin leveraged the Neuroute platform's analytics capabilities to dive deep into the scientific validity and clinical feasibility of using voice technology for the diagnosis of these SMIs.
Indication-Specific Feasibility: Psyrin focused their efforts on the analysis of Bipolar Disorder and Schizophrenia within the UK. Utilizing Neuroute's advanced data analytics, they collaborated with healthcare experts to scrutinize the prevalence rates, treatment methods, and other intricacies related to these specific SMIs. This allowed Psyrin to adapt their technology to better meet the needs of these patient demographics.
Landscape Analysis: A comprehensive landscape analysis was conducted. Using Neuroute's advanced analytics and data visualization features, they assessed patient demographics, existing treatment methodologies, and the potential for patient recruitment across the UK.
Site Analysis: Psyrin utilized Neuroute's site assessment tools to perform an exhaustive site analysis. They focused on healthcare facilities specialized in mental health treatments and, after rigorous evaluations through Neuroute, selected three high-capacity sites for the initial trials.
Conclusion
By employing Neuroute's versatile platform for every stage of their planning and implementation, Psyrin has set a new standard in the detection and treatment of Serious Mental Illnesses in the UK. This systematic approach has perfectly teed them up for the forthcoming large-scale clinical trials. By pinpointing the most suitable sites and adopting a patient-centric model analyzed through Neuroute, Psyrin is poised to revolutionize the way SMIs are diagnosed and treated, thus promising to impact millions of lives positively.
